The Institute for Clinical and Economic Review (ICER) is an independent nonprofit research institute that analyzes the value of medications at their current cost. ICER's assessment of cystic fibrosis therapies included ivacaftor (Kalydeco®), lumacaftor/ivacaftor (Orkambi®), and tezacaftor/ivacaftor (Symdeko®).

Overall, policymakers and public and private insurance companies are looking for more information to help them make informed coverage decisions and to better understand the value of therapies. ICER is one entity that has stepped in to try to fill this gap.

Throughout the development of their evaluation, ICER invited public comment to help inform and shape their assessment. The final report was published on May 3, 2018. It will be the subject of a public meeting hosted by ICER on May 17, 2018.

During the meeting, an independent panel will discuss and vote on the comparative clinical effectiveness, benefits or disadvantages, and other contextual considerations of the therapies. The implications of the vote will also be discussed among a roundtable of clinical experts and patients. On behalf of the Foundation, Mary Dwight, senior vice president of policy and advocacy, and Dr. Michael Boyle, senior vice president of therapeutics development, will be attending and presenting.  

See below for a list of our submitted, public comments:

• November 20, 2017 - Cystic Fibrosis Foundation Comments on ICER Draft Scoping Document
• April 12, 2018 - Cystic Fibrosis Foundation Comments on ICER Draft Evidence Report of CFTR Modulators
• May 3, 2018 - ICER Releases Final Evidence Report of CFTR Modulators. The Foundation posted a news story in response.